• The benefits of virtual learning webinars to both low- and high-income countries 

  Ng, M.; Chamileke, N.; Mapulanga, V.; Campain, N.; Payne, S. (Wiley, 2022-04-01)

  The coronavirus disease 2019 (COVID-19) pandemic has brought about many changes in the relationships between high-income countries and partner organisations in low- or low-middle-income countries, such as predominate in ...

• 811 DELIRIUM IN COVID-19: COMMON AND CLINICALLY SIGNIFICANT: EXPERIENCES FROM THE NIGHTINGALE HOSPITAL EXETER 

  Reed, W; Fearnley, C; Tregarthen, A; Hubbard, J; Griffiths, J; Whitehead, T; Hacon, J; Anning, L (Oxford University Press, 2022-03-08)

  Delirium is an independent predictor of mortality in patients admitted with community-acquired pneumonia (Pieralli, 2014), but significance and incidence in Covid-19 infection has not been established. The Nightingale ...

• Providing information, care and support to IBD patients during the pandemic 

  Cairnes, V. (MA Healthcare, 2022-03-24)

  Vida Cairnes, Lead Inflammatory Bowel Disease (IBD) Nurse Specialist, Royal Devon and Exeter Hospital, and the Exeter IBD Specialist Nursing Team were runners-up in the Gastrointestinal/IBD Nurse of the Year category of ...

• P361 PREPARE-IBD: Physician Responses to disease Flares and Patient Adaptation in Relation to Events in Inflammatory Bowel Disease during the COVID-19 pandemic: A multicentre cohort analysis 

  Saifuddin, A; Kent, A; Mehta, S; Hicks, L; Gonzalez, H; Segal, J; Brooks, M; Subramanian, S; Bhala, N; Conley, T; Patel, K; Lamb, C; Walker, G; Kennedy, N; Sebastian, S; collaborators, PREPARE-IBD (Oxford University Press, 2022-01-21)

  The COVID-19 pandemic continues to pose complex problems across Europe and the world, with rising numbers of infections and the ongoing need for drastic public health interventions. This is difficult for patients with ...

• Pneumomediastinum in COVID-19: a phenotype of severe COVID-19 pneumonitis? The results of the United Kingdom (POETIC) survey 

  Melhorn, J.; Achaiah, A.; Conway, F. M.; Thompson, E. M. F.; Skyllberg, E. W.; Durrant, J.; Hasan, N. A.; Madani, Y.; Naran, P.; Vijayakumar, B.; Tate, M. J.; Trevelyan, G. E.; Zaki, I.; Doig, C. A.; Lynch, G.; Warwick, G.; Aujayeb, A.; Jackson, K. A.; Iftikhar, H.; Noble, J. H.; Ng, Aykc; Nugent, M.; Evans, P. J.; Hastings, R. A.; Bellenberg, H. R.; Lawrence, H.; Saville, R. L.; Johl, N. T.; Grey, A. N.; Ellis, H. C.; Chen, C.; Jones, T. L.; Maddekar, N.; Khan, S. L.; Muhammad, A. I.; Ghani, H.; Myint, Y. M. M.; Rafique, C.; Pippard, B. J.; Irving, B. R. H.; Ali, F.; Asimba, V. H.; Azam, A.; Barton, E. C.; Bhatnagar, M.; Blackburn, M. P.; Millington, K. J.; Budhram, N. J.; Bunclark, K. L.; Sapkal, T. P.; Dixon, G.; Harries, A. J. E.; Ijaz, M.; Karunanithi, V.; Naik, S.; Khan, M. A.; Savlani, K.; Kumar, V.; Gallego, B. L.; Mahdi, N. A.; Morgan, C.; Patel, N.; Rowlands, E. W.; Steward, M. S.; Thorley, R. S.; Wollerton, R. L.; Ullah, S.; Smith, D. M.; Lason, W.; Rostron, A. J.; Rahman, N. M.; Hallifax, R. J. (European Respiratory Society, 2022-02-10)

  BACKGROUND: There is an emerging understanding that coronavirus disease 2019 (COVID-19) is associated with increased incidence of pneumomediastinum. We aimed to determine its incidence among patients hospitalised with ...

• The impact of COVID-19 upon the delivery of exercise services within cystic fibrosis clinics in the United Kingdom 

  Tomlinson, O. W.; Saynor, Z. L.; Stevens, D.; Urquhart, D. S.; Williams, C. A. (Wiley Open Access, 2022-03-01)

  OBJECTIVES: The COVID-19 pandemic has resulted in unprecedent changes to clinical practice, and as the impact upon delivery of exercise services for people with cystic fibrosis (CF) in the United Kingdom was unknown, this ...

• Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab 

  Lin, S.; Kennedy, N. A.; Saifuddin, A.; Sandoval, D. M.; Reynolds, C. J.; Seoane, R. C.; Kottoor, S. H.; Pieper, F. P.; Lin, K. M.; Butler, D. K.; Chanchlani, N.; Nice, R.; Chee, D.; Bewshea, C.; Janjua, M.; McDonald, T. J.; Sebastian, S.; Alexander, J. L.; Constable, L.; Lee, J. C.; Murray, C. D.; Hart, A. L.; Irving, P. M.; Jones, G. R.; Kok, K. B.; Lamb, C. A.; Lees, C. W.; Altmann, D. M.; Boyton, R. J.; Goodhand, J. R.; Powell, N.; Ahmad, T. (Nature, 2022-03-16)

  Anti tumour necrosis factor (anti-TNF) drugs increase the risk of serious respiratory infection and impair protective immunity following pneumococcal and influenza vaccination. Here we report SARS-CoV-2 vaccine-induced ...

• COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study 

  Alexander, J. L.; Kennedy, N. A.; Ibraheim, H.; Anandabaskaran, S.; Saifuddin, A.; Castro Seoane, R.; Liu, Z.; Nice, R.; Bewshea, C.; D'Mello, A.; Constable, L.; Jones, G. R.; Balarajah, S.; Fiorentino, F.; Sebastian, S.; Irving, P. M.; Hicks, L. C.; Williams, H. R. T.; Kent, A. J.; Linger, R.; Parkes, M.; Kok, K.; Patel, K. V.; Teare, J. P.; Altmann, D. M.; Boyton, R. J.; Goodhand, J. R.; Hart, A. L.; Lees, C. W.; Ahmad, T.; Powell, N. (Elsevier, 2022-04-01)

  BACKGROUND: The effects that therapies for inflammatory bowel disease (IBD) have on immune responses to SARS-CoV-2 vaccination are not yet fully known. Therefore, we sought to determine whether COVID-19 vaccine-induced ...

• The Population-Wide Risk-Benefit Profile of Extending the Primary COVID-19 Vaccine Course Compared with an mRNA Booster Dose Program 

  Shiri, T.; Evans, M.; Talarico, C. A.; Morgan, A. R.; Mussad, M.; Buck, P. O.; McEwan, P.; Strain, W. D. (MDPI, 2022-01-18)

  The vaccination program is reducing the burden of COVID-19. However, recently, COVID-19 infections have been increasing across Europe, providing evidence that vaccine efficacy is waning. Consequently, booster doses are ...

• Self-experimentation in the COVID Era: Is it morally justifiable? - A perspective 

  Sinha, A.; Njere, I.; Sinha, C. K. (Elsevier, 2022-01-01)

• A survey among physicians in surgery and anesthesiology departments after the first surge of SARS-CoV-2 infections in Germany : Preparing for further challenges ahead 

  Grishina, A.; Link, F.; Arend, A.; Kleemann, F.; Tober-Lau, P.; Andree, D.; Münn, F.; Gruendl, M.; Quante, M.; Lederhuber, H.; Albertsmeier, M.; Struller, F.; Grützmann, R.; Königsrainer, A.; Löffler, M. W. (Springer, 2022-01-21)

  BACKGROUND: The SARS-CoV‑2 pandemic has extensively challenged healthcare systems all over the world. Many elective operations were postponed or cancelled, changing priorities and workflows in surgery departments. AIMS: ...

• OP21 COVID-19 vaccine-induced antibody responses are impaired in Inflammatory Bowel Disease patients treated with infliximab, ustekinumab or tofacitinib, but not thiopurines or vedolizumab 

  Alexander, J; Kennedy, N; Ibraheim, H; Anandabaskaran, S; Saifuddin, A; Castro Seoane, R; Liu, Z; Nice, R; Bewshea, C; D’Mello, A; Constable, L; Jones, G R; Balarajah, S; Fiorentino, F; Sebastian, S; Irving, P M; Hicks, L; Williams, H; Kent, A; Linger, R; King, R; Parkes, M; Kok, K; Patel, K; Altmann, D; Boyton, R; Goodhand, J; Hart, A; Lees, C; Ahmad, T.; Powell, N

  Robust COVID-19 vaccine-induced antibody (Ab) responses are important for protective anti-viral immunity. Data are urgently needed to determine whether vaccine-induced immunity is impacted by commonly used immunosuppressive ...

• OP22 Antibody decay, T cell immunity and breakthrough infections following SARS-CoV-2 vaccination in infliximab- and vedolizumab-treated patients 

  Lin, S; Kennedy, N A; Saifuddin, A; Muñoz Sandoval, D; Reynolds, C J; Seoane, R C; Kottoor, S H; Pieper, F P; Lin, K M; Butler, D K; Chanchlani, N; Nice, R; Chee, D; Bewshea, C; Janjua, M; McDonald, T J; Sebastian, S; Alexander, J L; Constable, L; Lee, J C; Murray, C D; Hart, A L; Irving, P M; Jones, G R; Kok, K B; Lamb, C A; Lees, C W; Altmann, D M; Boyton, R J; Goodhand, J R; Powell, N; Ahmad, T.; IBD, CLARITY

  Antibody responses following SARS-CoV-2 infection or a single-dose of SARS-CoV-2 vaccine are impaired in patients with inflammatory bowel disease treated with anti-TNF compared to those treated with vedolizumab, a gut-selective ...

• A report from the NIHR UK working group on remote trial delivery for the COVID-19 pandemic and beyond 

  Masoli, J. A. H.; Down, K.; Nestor, G.; Hudson, S.; O'Brien, J. T.; Williamson, J. D.; Young, C. A.; Carroll, C. (BioMed Central, 2021-12-11)

  BACKGROUND: Prior to the COVID-19 pandemic, the majority of clinical trial activity took place face to face within clinical or research units. The COVID-19 pandemic resulted in a significant shift towards trial delivery ...

• Persistence of clinically relevant levels of SARS-CoV2 envelope gene subgenomic RNAs in non-immunocompromised individuals 

  Davies, M.; Bramwell, L. R.; Jeffery, N.; Bunce, B.; Lee, B. P.; Knight, B.; Auckland, C.; Masoli, J. A.; Harries, L. W. (Elsevier, 2021-12-07)

  OBJECTIVES: This study aimed to evaluate the associations between COVID-19 severity and active viral load, and to characterize the dynamics of active SARS-CoV-2 clearance in a series of archival samples taken from patients ...

• Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial 

  Munro, A. P. S.; Janani, L.; Cornelius, V.; Aley, P. K.; Babbage, G.; Baxter, D.; Bula, M.; Cathie, K.; Chatterjee, K.; Dodd, K.; Enever, Y.; Gokani, K.; Goodman, A. L.; Green, C. A.; Harndahl, L.; Haughney, J.; Hicks, A.; van der Klaauw, A. A.; Kwok, J.; Lambe, T.; Libri, V.; Llewelyn, M. J.; McGregor, A. C.; Minassian, A. M.; Moore, P.; Mughal, M.; Mujadidi, Y. F.; Murira, J.; Osanlou, O.; Osanlou, R.; Owens, D. R.; Pacurar, M.; Palfreeman, A.; Pan, D.; Rampling, T.; Regan, K.; Saich, S.; Salkeld, J.; Saralaya, D.; Sharma, S.; Sheridan, R.; Sturdy, A.; Thomson, E. C.; Todd, S.; Twelves, C.; Read, R. C.; Charlton, S.; Hallis, B.; Ramsay, M.; Andrews, N.; Nguyen-Van-Tam, J. S.; Snape, M. D.; Liu, X.; Faust, S. N. (Elsevier, 2021-12-18)

  BACKGROUND: Few data exist on the comparative safety and immunogenicity of different COVID-19 vaccines given as a third (booster) dose. To generate data to optimise selection of booster vaccines, we investigated the ...

• Venetoclax with Azacitidine or Low Dose Cytarabine As an Alternative to Intensive Chemotherapy in Fit Adults during the COVID19 Pandemic: Real World Data from the UK National Health Service 

  Othman, Jad; Amer, Mariam; Amofa, Ruebina; Anderson, Laura; Austin, Michael J; Bashford, Alex; Belsham, Edward; Boot, Jesca; Campbell, Victoria Louise; Coats, Thomas; Collins, Angela; Crawley, Charles; Crolla, Francesca; Cross, Joe W; Dalley, Chris; Dang, Raymond; Dennis, Mike; Dhawan, Saniya; Elliott, Johnathon; Galli, Sofia; Gallipoli, Paolo; Hodgson, Katherine; Jain, Manish; Kalkur, Pallavi; Katsomitrou, Vana; Khan, Anjum; Khwaja, Asim; Krishnamurthy, Pramila; Latif, Annie; Laurie, John; Lim, Michael; Loizou, Eleana; Loke, Justin; Mannari, Deepak; Manson, Cara; Marshall, Scott R.; Mobashwera, Behnaz; Murthy, Vidhya; Ochaya, Odong; Orthi, Shahzad; Palanicawandar, Renuka; Pillai, Srinivas; Radzova, Dominika; Rye, Adam; Saunders, Jamie; Smith, Matthew; Taussig, David; Taylor, Tom; Whitmill, Richard; Zhao, Rui; Freeman, Sylvie D; Craddock, Charles; Dillon, Richard

  BackgroundBased on early evidence of a high rate of coronavirus mortality in patients with acute myeloid leukaemia (AML) undergoing intensive chemotherapy (IC), the national health service (NHS) in the United Kingdom ...

• Critical limb ischaemia in the time of COVID-19: establishing ambulatory service provision 

  Chana, M.; Muse, S.; Ball, S.; Bennett, R.; McCarthy, R. (Royal College of Surgeons, 2021-12-23)

  INTRODUCTION: The coronavirus disease 2019 (COVID-19) pandemic enforced changes to healthcare services at a pace and extent not seen previously in the NHS. The Royal Devon and Exeter provides regional vascular surgery ...

• Gilteritinib for Relapsed Acute Myeloid Leukaemia with FLT3 Mutation during the COVID-19 Pandemic: Real World Experience from the UK National Health Service 

  Othman, Jad; Afzal, Usman; Amofa, Ruebina; Austin, Michael J; Bashford, Alex; Belsham, Edward; Byrne, Jennifer; Coats, Thomas; Dang, Raymond; Dennis, Mike; Dhawan, Saniya; Elliot, Johnathon; Francis, Sebastian; Gallipoli, Paolo; Hodgson, Katherine; Kallmeyer, Charlotte; Jain, Manish; Katsomitrou, Vana; Khan, Anjum; Khwaja, Asim; Kolade, Seye; Krishnamurthy, Pramila; Latif, Annie; Laurie, John; Lim, Michael; Loke, Ching Ting; Manson, Cara; Marshall, Scott R.; Mobashwera, Behnaz; Munisamy, Sreetharan; Murray, Duncan; Murthy, Vidhya; Palanicawandar, Renuka; Saunders, Jamie; Smith, Matthew; Smith, Katherine; Sternberg, Alex; Taussig, David; Taylor, Tom; Freeman, Sylvie D; Craddock, Charles; Dillon, Richard

  BackgroundEarly data suggest that patients undergoing salvage chemotherapy for relapsed or refractory (R/R) acute myeloid leukaemia (AML) have poor outcomes if infected with SARS-CoV-2, and nosocomial transmission has been ...

• Trends in 28-Day Mortality of Critical Care Patients With Coronavirus Disease 2019 in the United Kingdom: A National Cohort Study, March 2020 to January 2021 

  Dennis, J. M.; McGovern, A. P.; Thomas, N. J.; Wilde, H.; Vollmer, S. J.; Mateen, B. A. (Wolters Kluwer, 2021-11-01)

  OBJECTIVES: To determine whether the previously described trend of improving mortality in people with coronavirus disease 2019 in critical care during the first wave was maintained, plateaued, or reversed during the second ...

View more